Top-Rated StocksTop-RatedNASDAQ:BMEA Biomea Fusion (BMEA) Stock Price, News & Analysis $1.93 -0.05 (-2.53%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$1.92 -0.01 (-0.78%) As of 09/12/2025 05:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Biomea Fusion Stock (NASDAQ:BMEA) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Biomea Fusion alerts:Sign Up Key Stats Today's Range$1.91▼$1.9950-Day Range$1.53▼$2.0352-Week Range$1.29▼$13.07Volume527,598 shsAverage Volume541,657 shsMarket Capitalization$114.85 millionP/E RatioN/ADividend YieldN/APrice Target$14.80Consensus RatingBuy Company Overview Biomea Fusion, Inc. (NASDAQ:BMEA) is a clinical‐stage biopharmaceutical company headquartered in Carlsbad, California. The company is dedicated to the discovery and development of small molecule therapies that target epigenetic regulators implicated in cancer. By leveraging a proprietary chemistry and drug discovery platform, Biomea Fusion aims to design precision medicines that modulate gene expression pathways involved in the initiation and progression of hematological malignancies and solid tumors. The company’s lead clinical asset, BMF-219, is an orally bioavailable inhibitor of the menin–mixed‐lineage leukemia (MLL) protein–protein interaction. BMF-219 is currently undergoing early-phase clinical evaluation in patients with MLL-rearranged leukemias and other malignancies driven by dysregulated menin activity. In parallel, Biomea Fusion is advancing a pipeline of preclinical programs targeting additional epigenetic and chromatin-associated proteins, all developed using its integrated discovery platform. Founded in 2018, Biomea Fusion has assembled a multidisciplinary team of drug discovery scientists, clinical development experts and regulatory specialists. The company conducts its research and early clinical operations in the United States and is actively exploring collaborations to support later‐stage development and global commercialization. With its focus on epigenetic modulation in oncology, Biomea Fusion seeks to deliver novel treatment options for patients facing unmet medical needs.AI Generated. May Contain Errors. Read More Biomea Fusion Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks69th Percentile Overall ScoreBMEA MarketRank™: Biomea Fusion scored higher than 69% of companies evaluated by MarketBeat, and ranked 338th out of 954 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.6 / 5Analyst RatingBuy Consensus RatingBiomea Fusion has received a consensus rating of Buy. The company's average rating score is 3.17, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Upside PotentialBiomea Fusion has a consensus price target of $14.80, representing about 666.8% upside from its current price of $1.93.Amount of Analyst CoverageBiomea Fusion has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Biomea Fusion's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Biomea Fusion are expected to grow in the coming year, from ($3.93) to ($3.84) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biomea Fusion is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biomea Fusion is -0.64, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiomea Fusion has a P/B Ratio of 1.36. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Biomea Fusion's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.14% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 3.59%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBiomea Fusion does not currently pay a dividend.Dividend GrowthBiomea Fusion does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.14% of the float of Biomea Fusion has been sold short.Short Interest Ratio / Days to CoverBiomea Fusion has a short interest ratio ("days to cover") of 6.8.Change versus previous monthShort interest in Biomea Fusion has recently decreased by 3.59%, indicating that investor sentiment is improving. News and Social Media3.0 / 5News Sentiment1.40 News SentimentBiomea Fusion has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.93 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biomea Fusion this week, compared to 3 articles on an average week.Search Interest25 people have searched for BMEA on MarketBeat in the last 30 days. This is an increase of 108% compared to the previous 30 days.MarketBeat FollowsOnly 15 people have added Biomea Fusion to their MarketBeat watchlist in the last 30 days. This is a decrease of -17% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Biomea Fusion insiders have not sold or bought any company stock.Percentage Held by Insiders18.42% of the stock of Biomea Fusion is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions96.72% of the stock of Biomea Fusion is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Biomea Fusion's insider trading history. Receive BMEA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biomea Fusion and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. BMEA Stock News HeadlinesThis Biomea Fusion Insider Increased Their Holding By 200% Last YearSeptember 11, 2025 | finance.yahoo.comBiomea Fusion (BMEA) Gets a Buy from OppenheimerAugust 23, 2025 | theglobeandmail.com$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal. | Brownstone Research (Ad)Can Biomea Fusion (NASDAQ:BMEA) Afford To Invest In Growth?August 16, 2025 | finance.yahoo.comBiomea Fusion (BMEA) Q2 Loss Drops 44%August 5, 2025 | fool.comBiomea Fusion files $300M mixed securities shelfAugust 5, 2025 | msn.comBiomea Fusion Reports Second Quarter 2025 Financial Results and Corporate HighlightsAugust 5, 2025 | globenewswire.comBiomea Fusion Appoints Julianne Averill to its Board of DirectorsJuly 24, 2025 | globenewswire.comSee More Headlines BMEA Stock Analysis - Frequently Asked Questions How have BMEA shares performed this year? Biomea Fusion's stock was trading at $3.88 at the beginning of the year. Since then, BMEA shares have decreased by 50.3% and is now trading at $1.93. How were Biomea Fusion's earnings last quarter? Biomea Fusion, Inc. (NASDAQ:BMEA) announced its earnings results on Tuesday, August, 5th. The company reported ($0.51) EPS for the quarter, beating the consensus estimate of ($0.59) by $0.08. When did Biomea Fusion IPO? Biomea Fusion (BMEA) raised $120 million in an initial public offering (IPO) on Friday, April 16th 2021. The company issued 7,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan, Jefferies and Piper Sandler acted as the underwriters for the IPO. Who are Biomea Fusion's major shareholders? Top institutional shareholders of Biomea Fusion include Aisling Capital Management LP (5.45%), Federated Hermes Inc. (1.53%), Geode Capital Management LLC (0.73%) and Scotia Capital Inc. (0.68%). Insiders that own company stock include Bihua Chen, A2a Pharmaceuticals, Inc and Michael JM Hitchcock. View institutional ownership trends. How do I buy shares of Biomea Fusion? Shares of BMEA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Biomea Fusion own? Based on aggregate information from My MarketBeat watchlists, some other companies that Biomea Fusion investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Arista Networks (ANET), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/05/2025Today9/14/2025Next Earnings (Estimated)11/04/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BMEA CIK1840439 Webwww.biomeafusion.com Phone650-980-9099FaxN/AEmployees50Year FoundedN/APrice Target and Rating Average Price Target for Biomea Fusion$14.80 High Price Target$54.00 Low Price Target$3.00 Potential Upside/Downside+666.8%Consensus RatingBuy Rating Score (0-4)3.17 Research Coverage12 Analysts Profitability EPS (Trailing Twelve Months)($3.03) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$138.43 million Net MarginsN/A Pretax MarginN/A Return on Equity-243.95% Return on Assets-140.74% Debt Debt-to-Equity RatioN/A Current Ratio3.68 Quick Ratio3.68 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.42 per share Price / Book1.36Miscellaneous Outstanding Shares59,509,000Free Float48,547,000Market Cap$114.85 million OptionableOptionable Beta-0.13 5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:BMEA) was last updated on 9/15/2025 by MarketBeat.com Staff From Our PartnersOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredRetire Comfortably with These New Monthly Income ETFs?Too many retirees lie awake at night, worried their savings won’t last. Traditional advice and tiny returns ju...Investors Alley | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomea Fusion, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomea Fusion With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.